HEK293T cells were grown at 37°C to approximately 80% confluence in 10 cm 175 tissue culture dishes using DMEM with 5% Hyclone Fetal Clone II (GE Healthcare 176 Lifesciences, Logan, UT) and 1X antibiotic and antimycotic (Gibco, Grand Island, NY) . 177 Expression plasmids containing the heavy and light chain sequences for KPF1 were 178 transfected into HEK293T cells using jetPRIME transfection reagent (PolyPlus, New 179 York, NY) as previously described [19] . Media was harvested and replenished three 180 times over 8 days. IgG was purified from culture supernatant using Magne Protein A 181 beads (Promega, Madison, WI) and the elution buffer exchanged with PBS using 182 Amicon Ultra centrifugal filters (Millipore-Sigma, Cork, Ireland). Plant expression vectors were assembled using standard recombinant DNA 185 technology, as previously described [51] . The KPF1-Antx and isotype control antibody 186 expression vectors, which included heavy chain (HC) and light chain (LC) genes, were 187 co-expressed with an oligosaccharyltransferase from Leishmania major (LmSTT3D) 188 known to enhance N-glycan occupancy of recombinant proteins, using a similar 189 strategy to that previously described [52] . In addition, a third expression vector was 
193
KPF1-Antx was produced as outlined in Figure 1A . Briefly and incubated with serially 10-fold diluted HEK-or Antx-produced KPF1 hMAbs in PBS 220 (starting concentration of 10 µg/ml). Binding was detected with HRP-conjugated anti-221 human IgG (Jackson ImmunoResearch, PA, USA). In selected ELISAs, increasing 222 concentrations of urea (ranging from 0 to 8 M) were added and the plates incubated for 223 15 min at room temperature prior to detection with anti-IgG-HRP to evaluate avidity. 326 We initially characterized the KPF1 hMAbs generated from either HEK293T cells 327 (KPF1-HEK) or tobacco plants (KPF1-Antx) in vitro (Figure 2) . Serially 2-fold diluted 328 (2.5 µg to 0.313 µg) KPF1-HEK and KPF1-Antx hMAbs showed similar characteristics 329 by SDS-PAGE (Figure 2A) and Western blot (Figure 2B) 
Reactivity of KPF1-Antx and KPF1-HEK hMAbs in vitro

Cross-reactivity of KPF1-Antx hMAb to H1N1 IAV 343
To characterize the ability of the KPF1-HEK and KPF1-Antx hMAbs to recognize 344 native IAV HA proteins, MDCK cells were infected (MOI 10) with Brisbane/H1N1, 345 16 pH1N1, NC/H1N1, PR8 /H1N1, WI/H1N1, GA/H1N1, or Brisbane/H3N2 and binding 346 was evaluated and quantified by IFA (Figure 3) . Both KPF1-Antx and KPF1-HEK 347 hMAbs recognized all H1N1 IAVs, but not Brisbane/H3N2 or mock-infected cells 348 (Figure 3A) . Quantifying the KPF1-HEK and KPF1-Antx hMAbs binding reactivity to 349 infected MDCK cells revealed that KPF1-Antx hMAb showed similar levels of 
Broad neutralization and hemagglutination inhibition activity by KPF1-Antx
355 hMAb 356 We next evaluated the ability of KPF1-Antx hMAb to neutralize a broad range of 357 H1N1 IAV, similar to previously described with KPF1-HEK hMAb [19] . Both KPF1-Antx 358 and KPF1-HEK hMAbs showed similar cross-reactivity, as assessed by IFA, against 359 different H1N1 viruses (Figure 3A) . Importantly, quantification of the IFA results 360 indicates that the ability of KPF1-Antx hMAb to recognize the IAV H1 in infected cells is 361 not statistically different than that of KPF1-HEK hMAb (Figure 3B) . Likewise, KPF1-362 Antx hMAb is able to similarly neutralize Brisbane/H1N1, pH1N1, NC/H1N1, WI/H1N1, 363 and GA/H1N1 strains (NT50 KPF1-Antx = 0.195 to 0.780 μg/ml; NT50 KPF1-HEK = 0.195 364 to 1.106 μg/ml), while neutralization of PR8/H1N1 was slightly less efficient (NT50 KPF1-365 Antx = 12.5 μg/ml; NT50 KPF1-HEK = 25.0 μg/ml) ( Table 1) . As expected, KPF1 hMAbs 366 were not able to neutralize Brisbane/H3N2 IAV, even at the highest concentration (200 367 μg/ml). Both KPF1-Antx and KPF1-HEK hMAbs also showed similar HAI activity against 368 H1N1 IAV and were potent for Brisbane/H1N1, pH1N1, WI/H1N1, and GA/H1N1(HAI = 369 0.271 to 1.106 μg/ml) but less efficient for NC/H1N1 and PR8/H1N1 (HAI = 8.714 to 370 17.425 μg/ml) strains ( Table 1) . 371 
Prophylactic activity of KPF1-Antx hMAb in vivo 372
To evaluate the protective efficacy of KPF1-Antx hMAb, Hartley guinea pigs 373 (N=3/group) received 20 mg/kg of either KPF1-Antx or isotype-Antx control hMAbs 6 h 374 prior to infection with 10 3 PFU of pH1N1 (Figure 4A) . Sentinel guinea pigs (N=3/group) 375 were put in contact with the infected guinea pigs at 1 d p.i. to assess viral transmission.
376
In the KPF1-Antx hMAb treated group, only one infected guinea pig and its sentinel 377 guinea pig showed restricted viral infection and shedding, respectively, in the nasal 378 washes (Figures 4B and C) . Contrarily, all infected guinea pigs treated with the isotype-379 Antx hMAb control showed higher levels of viral replication (Figure 4B) . Also, we 380 observed viral shedding that resulted in efficient transmission to sentinel guinea pigs in 381 all animals treated with the isotype-Antx hMAb (Figure 4C) . Importantly, gross 382 pathology supported that KPF1-Antx hMAb has prophylactic activity (Figures 4D-4F) . 383 Both, infected and sentinel guinea pigs in the KPF1-Antx hMAb treated group showed 384 mild or no multifocal consolidation, congestion and atelectasis in middle and caudal 385 lobes (Figures 4D and E, respectively) , while the isotype-Antx hMAb control treated 386 group infected (Figure 4D) and sentinel (Figure 4E ) guinea pigs showed more severe 387 pathology. Distribution of pathologic lesions on the lung surfaces were measured and 388 compared, and supports the gross observation that the KPF1-Antx hMAb treated group 389 showed lower lesion values (13.85 to 31.51 %) than those of the Isotype-Antx control 390 hMAb group (32.81 to 37.05 %) (Figure 4F) . 391 
Therapeutic activity of KPF1-Antx hMAb in vivo 392
To assess the therapeutic activity of the KPF1-Antx hMAb, guinea pigs (N=3/group) 393 were infected with 10 3 PFU of pH1N1 and then treated, 24 h p.i., with 20 mg/kg of either 394 KPF1-Antx or isotype-Antx control hMAbs. Sentinel guinea pigs (N=3/group) were put in 395 contact with the infected guinea pigs at 2 d p.i. (Figure 5A) and evaluated for viral 396 infection and shedding by determining viral titers in the nasal washes (Figures 5B and   397 5C, respectively). We observed high viral titers in infected guinea pigs treated with 398 KPF1-Antx and the isotype-Antx control hMAbs at 2 d p.i. However, from 3 d p.i., the 399 KPF1-Antx hMAb treated group showed lower levels of viral replication in one of the 400 infected guinea pigs and no viral shedding in the two other infected guinea pigs as 401 compared with the isotype-Antx-treated control group (Figure 5B) . Importantly, no virus 402 was detected in the sentinel guinea pig group that were put in contact with the infected 403 KPF1-Antx hMAb (Figure 5C) . As expected, gross pathologic observation of the KPF1-
404
Antx hMAb treated group showed only mild locally extensive congestion and atelectasis 405 in caudal lobes and surface lesion score ranging from 12.13 to 25.07 % (Figure 5F) , 406 while guinea pigs in the isotype-Antx hMAb treated group had more severe and larger 407 distribution of pathologic lesions affecting middle and caudal lobes and surface lesion 408 score, ranging from 34.03 to 37.20 %, (Figure 5F) . Altogether, these results 409 demonstrate that the plant-produced KPF1-Antx hMAb has both prophylactic and 410 therapeutic activity against pH1N1, including the ability to prevent viral transmission, in 411 guinea pigs. 
Discussion
415
To date, FDA-licensed vaccines and antivirals are the most effective methods to 416 prevent and/or control influenza viral infections. However, influenza vaccines require at 417 least 2 weeks after administration to induce protective immune responses against viral 418 infection. In the case of antivirals, their effectiveness is dependent on being 419 administered within 48 h after appearance of symptoms [59, 60] . Importantly, antiviral-420 resistant strains have been described [1, [24] [25] [26] . Consequently, these prevention and 421 treatment methods still leave substantial public health vulnerabilities.
422
In a previous study, we described a HEK293T-produced KPF1 hMAb (KPF1-HEK) 423 that shows broad binding and neutralizing activity against H1N1 IAV isolates in vitro and 424 potent prophylactic and therapeutic activities in vivo [19] , because of its ability to bind to 425 a conserved residue in the H1 hemagglutinin globular head of IAV [19] . In our current 426 study, we examine the efficacy of a plant-produced KPF1 hMAb (KPF1-Antx) that 427 possesses similar in vitro and in vivo properties to KPF1-HEK hMAb. KPF1-Antx was 428 produced in N. benthamiana plants using the vivoXPRESS ® platform (Figure 1A) , 429 where four-week old plants were infiltrated with Agrobacteria containing expression 430 vectors. Purified hMAb was recovered just seven days after infiltration from the foliage 431 using standard antibody purification techniques. SDS-PAGE (Figure 2A) and SEC- 
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